Departments of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niao-Song Dist, Kaohsiung City, 83301, Taiwan.
Department of Pathology, An Nan Hospital, China Medical University, No. 66, Sec.2, Changhe Road, Annan Dist, Tainan City, 709, Taiwan.
BMC Cancer. 2018 Jan 30;18(1):105. doi: 10.1186/s12885-018-4025-2.
Galectin-1, a radioresistance marker, was found in our previous study to be a prognostic factor for cervical cancer. The aim of current study is to determine the prognostic significance of the galectin-1 expression level in patients with glioblastoma multiforme (GBM) undergoing adjuvant radiotherapy (RT).
We included 45 patients with GBM who were treated with maximal safe surgical resection or biopsy alone followed by adjuvant RT of EQD2 (equivalent dose in 2-Gy fractions) > or = 60 Gy for homogeneous treatment. Paraffin-embedded tissues acquired from the Department of Pathology were analyzed using immunohistochemical staining for galectin-1 expression. The primary endpoint was overall survival (OS).
Patients with weak expression had a better median survival (27.9 months) than did those with strong expression (10.7 months; p = 0.009). We compared characteristics between weak and strong galectin-1 expression, and only the expression level of galectin-3 showed a correlation. The group with weak galectin-1 expression displayed a 3-year OS of 27.3% and a 3-year cancer-specific survival (CSS) of 27.3%; these values were only 5.9% and 7.6%, respectively, in the group with strong galectin-1 expression (p = 0.009 and 0.020, respectively). Cox regression was used to confirm that the expression level of galectin-1 (weak vs. strong) is a significant factor of OS (p = 0.020) and CSS (p = 0.022). Other parameters, such as the expression level of galectin-3, Eastern Cooperative Oncology Group (ECOG) performance, gender, surgical method, age ≥ 50 years, tumor size, or radiation field were not significant factors.
The expression level of galectin-1 affects survival in patients with GBM treated with adjuvant RT. Future studies are required to analyze the effect of other factors, such as O(6)-methylguanine-DNA methyltransferase (MGMT)-promoter methylation status, in patients with weak and strong galectin-1 expression.
在我们之前的研究中发现，半乳糖凝集素-1 是一种放射抵抗标志物，可作为宫颈癌的预后因素。本研究旨在确定半乳糖凝集素-1 表达水平对接受辅助放疗（RT）的多形性胶质母细胞瘤（GBM）患者的预后意义。
我们纳入了 45 名接受最大限度安全手术切除或单纯活检后接受 EQD2（2-Gy 分数等效剂量）> = 60 Gy 同源治疗的 GBM 患者。使用免疫组织化学染色对半乳糖凝集素-1 表达进行分析，从病理科获得石蜡包埋组织。主要终点为总生存期（OS）。
弱表达组的中位生存期（27.9 个月）优于强表达组（10.7 个月；p = 0.009）。我们比较了弱和强半乳糖凝集素-1 表达之间的特征，只有半乳糖凝集素-3 的表达水平有相关性。弱半乳糖凝集素-1 表达组的 3 年 OS 为 27.3%，3 年癌症特异性生存率（CSS）为 27.3%；强半乳糖凝集素-1 表达组分别为 5.9%和 7.6%（p = 0.009 和 0.020）。Cox 回归证实，半乳糖凝集素-1 表达水平（弱 vs. 强）是 OS（p = 0.020）和 CSS（p = 0.022）的显著因素。其他参数，如半乳糖凝集素-3 的表达水平、东部肿瘤协作组（ECOG）表现、性别、手术方法、年龄≥50 岁、肿瘤大小或照射野，均不是显著因素。
半乳糖凝集素-1 的表达水平影响接受辅助 RT 的 GBM 患者的生存。未来需要分析其他因素（如 O(6)-甲基鸟嘌呤-DNA 甲基转移酶（MGMT）启动子甲基化状态）对半乳糖凝集素-1 弱和强表达患者的影响。
